Latest Sustainability News

Australian Strategic Materials (ASM) reports significant progress in Q2 2025, including its first commercial heavy rare earth metals sale and a transformative low-cost production pathway at its Dubbo Project.

PointsBet has firmly dismissed Betr Entertainment’s unsolicited scrip takeover proposal, endorsing instead MIXI Australia’s superior all-cash offer. The board highlights significant risks and uncertainties tied to Betr’s bid while unanimously recommending shareholders accept MIXI’s $1.20 per share offer.

Paladin Energy outlines FY2026 operational ramp-up and financial guidance for its Langer Heinrich Mine, projecting increased uranium production and steady cost control ahead of full-scale operations in FY2027.

Brookside Energy reports robust early production from its ninth horizontal well in the SWISH Play, delivering solid cash flow and promising project economics.

Generation Development Group reports a transformative FY25 with record Investment Bond sales and successful integration of Evidentia and Lonsec managed accounts, setting the stage for strong growth in FY26.

Iluka Resources has met its full-year zircon-in-concentrate production guidance by mid-2025 while progressing key projects like Balranald and Eneabba amid ongoing global trade uncertainties.

Magnetic Resources NL’s Feasibility Study confirms a robust standalone development for its Lady Julie Gold Project in Western Australia, projecting over 1 million ounces of gold production across nine years with strong financial returns.

Vulcan Energy has won up to €104 million in grants from German federal and state governments to advance its sustainable lithium production project, bolstering Europe’s electric vehicle battery supply chain.

Westgold Resources reported a strong finish to FY25 with 82km of drilling and a $9 million investment in exploration, highlighted by a maiden 2.3 million ounce gold resource at Beta Hunt’s Fletcher zone.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.